Scala Biodesign raised $16M Series A led by Grove Ventures for ScalaOS, an AI protein design platfor...
The AMW Read
This is an incremental funding update for a player in the AI-driven protein design sub-segment of Vertical AI Healthcare/Bio.
NoveltySignificance
Healthcare & Bio · Player Map
Scala Biodesign raised $16M Series A led by Grove Ventures for ScalaOS, an AI protein design platform used by 9 of the top 20 pharma companies. 🧬 The platform combines LLMs, physics-based modeling and evolutionary data to optimize proteins in a single design cycle, replacing years of iterative lab experiments. Backed by 150+ scientific publications from a decade of Weizmann Institute research, this signals AI-driven protein engineering is becoming core drug development infrastructure. 💊
#ProteinEngineering #AIinPharma #DrugDiscovery #BiotechFunding #ComputationalBiology